12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dermagraft regulatory update

Shire said Health Canada approved Dermagraft human fibroblast-derived dermal substitute to treat diabetic foot ulcers. The company plans to launch the...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >